Peter Enzinger
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Surgical Treatments
- Gastroenterology top 0.2%
- Gastrointestinal Tumor Research and Treatment
Papers in
- Oncology 54
- Colorectal Cancer Treatments and Studies 25
- Pancreatic and Hepatic Oncology Research 14
- Cancer Immunotherapy and Biomarkers 12
-
- Gastric Cancer Management and Outcomes 49
- Co-authors
- Robert J. Mayer (8 shared papers)Charles S. Fuchs (35 shared papers)Jeffrey William Clark (27 shared papers)David P. Ryan (24 shared papers)Jeffrey A. Meyerhardt (26 shared papers)Matthew H. Kulke (23 shared papers)Keith E. Stuart (8 shared papers)Lawrence Scott Blaszkowsky (13 shared papers)
- Journals
- Journal of Clinical Oncology (20 papers)Annals of Oncology (18 papers)Journal of the National Comprehensive Cancer Network (15 papers)The Oncologist (6 papers)Cancer (5 papers)
- Partner nations
- United StatesJapanSouth Korea
In The Last Decade
Peter Enzinger
142 papers receiving 20.0k citations
Peter Enzinger's Hit Papers
Peers
Comparison fields: 5 of 144
- Oncology 7.9k
- Gastroenterology 1.1k
- Pulmonary and Respiratory Medicine 5.6k
- Surgery 6.3k
- Cancer Research 1.7k
Countries citing papers authored by Peter Enzinger
This map shows the geographic impact of Peter Enzinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Enzinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Enzinger more than expected).
Fields of papers citing papers by Peter Enzinger
This network shows the impact of papers produced by Peter Enzinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Enzinger. The network helps show where Peter Enzinger may publish in the future.
Co-authors
The 25 scholars most cited alongside Peter Enzinger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 146 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Esophageal Cancer Hit paper breakdown → | 2003 | 2252 |
| 2 | Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Hit paper breakdown → | 2018 | 1481 |
| 3 | Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology Hit paper breakdown → | 2022 | 1167 |
| 4 | Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study Hit paper breakdown → | 2021 | 1116 |
| 5 | Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology Hit paper breakdown → | 2017 | 1086 |
| 6 | Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer Hit paper breakdown → | 2020 | 872 |
| 7 | Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer Hit paper breakdown → | 2020 | 832 |
| 8 | Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology Hit paper breakdown → | 2019 | 809 |
| 9 | Colon Cancer Hit paper breakdown → | 2009 | 593 |
| 10 | Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial Hit paper breakdown → | 2023 | 520 |
| 11 | 2006 | 426 | |
| 12 | Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial Hit paper breakdown → | 2023 | 417 |
| 13 | Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus Hit paper breakdown → | 2018 | 403 |
| 14 | 2009 | 391 | |
| 15 | 2009 | 390 | |
| 16 | 2006 | 331 | |
| 17 | 2014 | 323 | |
| 18 | Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology Hit paper breakdown → | 2023 | 320 |
| 19 | 2008 | 316 | |
| 20 | 2008 | 257 |
About Peter Enzinger
Peter Enzinger is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Gastroenterology and Pathology and Forensic Medicine, having authored 146 papers that have together received 20.4k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (49 papers), Esophageal Cancer Research and Treatment (39 papers), Colorectal Cancer Treatments and Studies (25 papers), Pancreatic and Hepatic Oncology Research (14 papers), Gastrointestinal Tumor Research and Treatment (12 papers), Cancer Immunotherapy and Biomarkers (12 papers), Colorectal and Anal Carcinomas (7 papers) and Genetic factors in colorectal cancer (6 papers). The work is most often cited by research in Oncology (7.9k citations), Gastroenterology (1.1k citations), Pulmonary and Respiratory Medicine (5.6k citations), Surgery (6.3k citations) and Cancer Research (1.7k citations). Peter Enzinger has collaborated with scholars based in United States, Japan and South Korea. Frequent co-authors include Robert J. Mayer, Charles S. Fuchs, Jeffrey William Clark, David P. Ryan, Jeffrey A. Meyerhardt, Matthew H. Kulke, Keith E. Stuart, Lawrence Scott Blaszkowsky, Alona Muzikansky and Andrew Xiuxuan Zhu. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of the National Comprehensive Cancer Network, The Oncologist and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.